Active, not recruitingPhase 3NCT06625398
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
Studying Medullary sponge kidney
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Viridian Therapeutics, Inc.
- Intervention
- VRDN-003(drug)
- Enrollment
- 195 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- Scottsdale Clinical Trials, Scottsdale, Arizona, United States
- Alliance Research Institute - Canoga Park, Canoga Park, California, United States
- Marvel Clinical Research, Huntington Beach, California, United States
- United Medical Research Institute, Inglewood, California, United States
- Advancing Research International, LLC, Los Angeles, California, United States
- Roski Eye Institute, Keck School of Medicine, USC, Los Angeles, California, United States
- Alliance Research Institute - Lynwood, Lynwood, California, United States
- A.P.J. Office, Newport Beach, California, United States
- Byers Eye Institute at Stanford University, Palo Alto, California, United States
- Pasadena Clinical Trials, Pasadena, California, United States
- Senta Clinic, San Diego, California, United States
- Ilumina Medical Research, Kissimmee, Florida, United States
- Med-Care Research, Miami, Florida, United States
- Hype Clinical Research LLC, Miami, Florida, United States
- Anmed Health Services LLC, Miami, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06625398 on ClinicalTrials.govOther trials for Medullary sponge kidney
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07489131Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular EdemaAlvotech Swiss AG
- RECRUITINGPHASE2NCT07441642A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationNovartis Pharmaceuticals
- ENROLLING BY INVITATIONPHASE2NCT07395986A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related CataractOcusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
- RECRUITINGPHASE2NCT07400965Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex BlepharitisGlaukos Corporation
- RECRUITINGPHASE3NCT07235085A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyOcular Therapeutix, Inc.
- RECRUITINGPHASE2NCT07128628A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseBausch & Lomb Incorporated
- RECRUITINGPHASE3NCT06990399A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKKodiak Sciences Inc
- RECRUITINGPHASE3NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration4D Molecular Therapeutics